The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes
© Cable et al.; licensee BioMed Central Ltd. 2014
Received: 15 November 2013
Accepted: 13 February 2014
Published: 4 March 2014
Circulating endocannabinoid levels are increased in obesity and diabetes. We have shown that fatty acid amide hydrolase (FAAH, an endocannabinoid hydrolysing enzyme) in subcutaneous adipose tissue positively correlates with BMI in healthy volunteers. The aim of the present study was to investigate whether the hydrolytic enzymes of the endocannabinoid system are affected by diabetes or metabolic syndrome in obesity.
Using radiolabelled substrates, FAAH and monoacylglycerol lipase (MGL) activities were assessed in adipocytes from various adipose depots in Zucker rats (n = 22, subcutaneous abdominal, visceral and epididymal) and bariatric patients (n = 28, subcutaneous abdominal and omental).
FAAH activity was significantly increased in adipocytes of obese (Zucker Fatty) compared to Zucker lean rats (P < 0.05) but was not raised in the Zucker Diabetic Fatty rats (ZDF). MGL activity was raised in both Zucker Fatty (P < 0.001-0.01) and ZDF rats (P < 0.05) and was positively correlated with body weight and plasma glucose levels (P < 0.01). In bariatric patients (BMI range 37–58 kg.m2), there was a trend for MGL activity to correlate positively with BMI, reaching significance when type 2 diabetic patients were removed. FAAH and MGL activities in obese humans were not correlated with blood pressure, skinfold thicknesses, fasting glucose, insulin, HbA1c, triglycerides or cholesterol levels.
FAAH in adipocytes is differentially altered in animal models of obesity and diabetes, while MGL activity is increased by both. However, in obese humans, FAAH or MGL activity in adipocytes is not affected by diabetes, dyslipidaemia or other markers of metabolic dysfunction. This suggests increased circulating levels of endocannabinoids are not a result of altered degradation in adipose tissue.
KeywordsEndocannabinoid Adipose Adipocyte Obesity Type 2 diabetes Fatty acid amide hydrolase (FAAH) Monoacylglycerol lipase (MGL) Rat Human
The endocannabinoid system (ECS) is crucial in the regulation of metabolism and energy homeostasis (see [1–4]). The ECS is comprised of endocannabinoid ligands, their receptors, and the enzymes required for their synthesis and degradation. N-arachidonoylethanolamide (anandamide, AEA)  and 2-arachidonoylglycerol (2-AG) [6, 7] are the two best characterised endocannabinoids, and the enzymes which degrade them are predominantly fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL) respectively [8, 9]. Other N-acylethanolamines such as oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are also degraded by FAAH.
It has been suggested that the ECS is upregulated in human obesity on the basis that plasma concentrations of AEA [10, 11], 2-AG  and other acyl-ethanolamides  correlate positively with body mass index (BMI). We have shown that FAAH activity in mature subcutaneous adipocytes correlates positively with BMI in healthy volunteers . However, BMI is a crude measure of adiposity and the adverse metabolic consequences of obesity are more closely related to centripetal obesity. It is therefore relevant that circulating 2-AG levels  and FAAH activity in subcutaneous adipocytes  also correlate with waist circumference, and the most significant rise in plasma 2-AG occurs in those with visceral obesity [11, 12].
The peripheral ECS may be dysregulated in type 2 diabetes, as first suggested in a study showing increased concentrations of AEA and 2-AG in plasma in patients with type 2 diabetes compared to BMI-matched controls . In subcutaneous adipose tissue, AEA is increased and 2-AG is decreased in obese humans with type 2 diabetes compared to lean and obese non-diabetic controls . Hyperinsulinaemia (using a clamp) also causes an upregulation of FAAH mRNA in subcutaneous abdominal adipose tissue of lean subjects, but no change in the obese group, in which FAAH was already chronically upregulated . However, any influence of hyperinsulinaemia or other metabolic factors on functional FAAH or MGL enzyme activity (as opposed to mRNA levels) have not been assessed.
Visceral adipose tissue is more metabolically active than subcutaneous adipose tissue , but there is conflicting evidence as to whether the ECS differs significantly between these depots. In subjects with a BMI less than 25 kg.m2, cannabinoid 1 (CB1) receptor mRNA expression is higher [19, 20], unchanged  or lower  in subcutaneous compared to visceral adipose tissue. In obese subjects, CB1 receptor mRNA expression is elevated [11, 19, 21] or not different  in visceral compared to subcutaneous adipose tissue. FAAH mRNA expression is increased  or unchanged  in visceral compared to subcutaneous adipose tissue. A higher expression of MGL mRNA in subcutaneous compared to visceral adipose  is consistent with increased levels of 2-AG reported in visceral adipose tissue . However, the catalytic activities of FAAH and MGL have not been compared between different adipose tissue depots.
In light of this background, the primary aim of the current study was to investigate if obesity co-morbidities and metabolic risk factors, including hyperinsulinaemia, hyperglycaemia and dyslipidaemia, influence FAAH and MGL enzyme activities in adipose tissue. The secondary aim was to determine whether FAAH or MGL activities differ between visceral and subcutaneous adipocytes. These objectives were first explored in rat models of obesity and type 2 diabetes, and subsequently in severely obese patients undergoing bariatric surgery.
The effects of obesity/diabetes on FAAH and MGL activity in Zucker rats
In subcutaneous adipocytes, MGL activities for the obese and obese diabetic rats were 18- and 12-fold increased compared to the lean animals (P < 0.01 and P < 0.05, Figure 2D). In abdominal adipocytes the corresponding values were 5- and 3-fold, respectively (P < 0.001 and P < 0.05, Figure 2E), and in epididymal adipocytes, MGL activity was 5- and 3.5-fold increased (P < 0.001 and P < 0.05, Figure 2F). A positive relationship was identified between MGL activity and body mass in all adipose tissues (abdominal r = 0.67, P < 0.001; subcutaneous r = 0.63, P < 0.01; epididymal r = 0.76, P < 0.0001, Figure 3D,E,F). MGL activity also correlated with blood glucose levels in adipocytes from all three adipose tissue depots (subcutaneous r = 0.53, P < 0.05; abdominal r = 0.56, P < 0.01; epididymal r = 0.48, P < 0.05), and this effect became stronger when the diabetic rats were removed (See Figure 3J,K,L).
The effects of adipose depots on FAAH and MGL activity
FAAH and MGL activity in obese patients
Characteristics of the patients included in this study
‘Healthy’ (n = 6)
Metabolic syndrome (n = 12)
Diagnosed T2D (n = 10)
Gender split (male: female)
44.0 ± 4.7
44.5 ± 3.3
45.5 ± 2.7
BMI (kg.m -2 )
44.0 ± 4.7
46.3 ± 1.7
44.8 ± 1.5
Insulin (mU.L -1 )
12.2 ± 3.1
14.0 ± 2.3
15.9 ± 1.9
Glucose (mmol.L -1 )
5.0 ± 0.2~
5.1 ± 0.2*
8.7 ± 1.4~*
5.8 ± 0.1†
5.8 ± 0.3#
7.9 ± 0.7†#
85.8 ± 26.2
71.4 ± 14.2
50.4 ± 6.8
96.1 ± 4.8
96.3 ± 4.3
104.8 ± 3.6
3 (1: ACE inhibitor; 2: ACE inhibitor + thiazide diuretic)
3 (1: ACE inhibitor; 1: ACE inhibitor + β1 antagonist; 1: ACE inhibitor + thiazide diuretic)
3 (2: ACE inhibitor; 1: thiazide diuretic)
The primary aim of this study was to determine whether the activities of FAAH and MGL, two key catabolic enzymes of the ECS, are differentially affected by diabetes or other markers of the metabolic syndrome in obesity. FAAH was raised in obese rats, but not obese diabetic rats, while MGL activity was elevated in both strains. FAAH and MGL activities positively correlated with body weight and blood glucose in the Zucker rats, but MGL activity correlated more strongly. By contrast, in severely obese humans, FAAH and MGL activity in adipose tissue was not correlated with adiposity and were not different between ‘healthy’, type 2 diabetic, metabolic syndrome patients, or in patients with clinical elevated blood glucose, poor glycaemic control or hyperlipidaemia. FAAH and/or MGL activities were not different between visceral and subcutaneous adipose tissue depots, except in the lean rats, where MGL activity was higher in visceral compared to subcutaneous adipocytes.
The effects of obesity/diabetes on FAAH and MGL activity in Zucker rats
We found that FAAH and MGL enzyme activities in mature adipocytes are increased in Zucker rats compared to lean rats, and were positively correlated with body mass in the rat strains MGL activity was also correlated with blood glucose levels, and this relationship was stronger when the diabetic rats were removed from analysis. A relationship between FAAH and blood glucose was also observed without the diabetic rats. Given that MGL has distinct roles in lipolysis and signalling, the increased activity of MGL in our studies may reflect an increase in the endocannabinoid signalling role of MGL rather than lipolysis, since lipolytic enzymes are generally repressed in obesity. MGL activity was raised in both the obese and obese diabetic rats suggesting a differential regulation of FAAH and MGL in diabetes in obesity. The physiological consequence of this differential effect of diabetes in obesity on enzyme activity is not clear. In obese diabetic humans, AEA, but not 2-AG, is increased in subcutaneous adipose tissue . An increase in AEA causing activation of CB1 could lead to unfavourable metabolic effects, however an increase in PEA and OEA, which are also degraded by FAAH , may be beneficial. For example, OEA decreases food intake and lowers hyperlipidaemia in obese rats via PPARα activation  and both OEA and PEA can stimulate insulin and GLP-1 secretion via activation of GPR119 [23, 24].
The effects of metabolic markers on FAAH and MGL activity in obese patients
Although we have shown in a healthy volunteer population that FAAH enzyme activity in mature subcutaneous adipocytes correlates with BMI (ranging from 19.1-33.8 kg.m-2, 13), in the current population of severely obese patients (BMIs 36.6 to 58.2 kg.m-2), there was no further correlation between FAAH activity and BMI, waist circumference, neck circumference or skinfold thicknesses. Interestingly, a 5% reduction in total body weight following calorie restriction does not affect FAAH mRNA  and a 10% weight loss in obese volunteers resulted in a decrease in FAAH mRNA in gluteal, but not abdominal, adipose tissue to levels lower than the lean controls . A possible conclusion from these findings is that there is limit to the enzymatic capacity of FAAH which no longer increases in proportion to BMI in our severely obese patients.
In contrast to the data with FAAH activity, and in accordance to the animal data, we found a trend for a positive correlation in the human bariatric patients between MGL and BMI (becoming significant without diabetic patients) and between MGL and adiposity in the female only population. This confirms the differential regulation of FAAH and MGL activity in adipocytes. Since FAAH is regulated by both insulin and leptin, we hypothesise that factors such as insulin and leptin resistance in obesity oppose any further increases in FAAH activity and that MGL must be under other regulating factors.
In obese patients, there was no difference in FAAH or MGL between patients with or without a diagnosis of type 2 diabetes, or those with clinically elevated plasma glucose, HbA1c or HOMA. Furthermore, no correlation was observed between serum insulin levels and FAAH or MGL activity. Together this suggests that within a severely obese population, these metabolic variables do not appear to influence FAAH or MGL activity. Similarly, elevated blood pressure, neck circumference, triglycerides, total cholesterol or HDL levels did not correlate with FAAH or MGL activity. However, it should be noted that our patients achieved reasonably good glycaemic control (HbA1c 7.9 ± 0.7), and were not hyperinsulinaemic. Therefore, the finding that FAAH activity was reduced in the ZDF rat and not diabetic humans might be ascribed to the fact that diabetes is uncontrolled in the ZDF, and this idea should be further pursued. Interestingly, another team reported that FAAH mRNA in subcutaneous adipose tissue correlated positively with blood glucose and insulin in men, but not in females , which may be important given that the majority of the patients in the current study were female. Indeed, we observed a significantly lower level of FAAH in our obese males. Any gender differences in the regulation of FAAH might explain why our predominantly female population did not show any significant relationship between FAAH activity and variables such as insulin sensitivity.
FAAH and MGL activities in different adipose depots
Visceral adipose tissue is thought to have greater metabolic activity and a greater impact on cardiovascular health . Differences between adipose depots have been reported for various components of the ECS. In obese humans, CB1 receptor mRNA is higher in visceral adipose tissue than subcutaneous [19, 21]. FAAH mRNA levels are the same between subcutaneous and visceral adipose tissue in obese humans , or higher in visceral than subcutaneous/gluteal adipose tissue in lean and obese humans . MGL is reported to be downregulated in visceral adipose tissue [21, 25]. No studies have been published on the activities of FAAH or MGL enzymes in adipocytes from different adipose tissue depots. In the present study, we found that FAAH and MGL activities were not different in paired subcutaneous and visceral adipocytes from obese patients. Similarly, no differences were observed between the rat strains in enzyme activity between adipose depots tested. This suggests that the rate of endocannabinoid degradation does not differ between visceral and subcutaneous mature adipocytes and it may be that differences in the expression of the ECS in the stromal-vascular fraction may account for the overall differences in mRNA observed in other studies between depots, or that enzyme mRNA does not reflect enzyme activities.
In summary, several previous studies have shown that in obese humans, circulating endocannabinoid levels and components of the ECS in adipose tissue are altered by insulin or diabetes. The results presented in this study show that FAAH and MGL enzyme activities are increased in adipocytes from animal model of diabetes/obesity. However, in subcutaneous mature adipocytes from severely obese humans, FAAH and MGL enzyme activities are not altered in relation to BMI, waist circumference, adipose tissue distribution, blood pressure, fasting glucose or insulin, glycaemic control or dyslipidaemia. Differences between the animal and human studies may be explained by gender, or differences in insulin (and potentially other hormones) sensitivity. No differences in the activity of FAAH or MGL were identified between subcutaneous and visceral adipocytes.
This study was approved by Derbyshire Regional Ethics Committee (08/H0401/94) and Royal Derby Hospital Trust (DHRD/2008/081), and recruited patients undergoing elective laparoscopic bariatric or cholecystectomy surgery at Royal Derby Hospital. Informed written consent was obtained in accordance with Good Clinical Practice and the Declaration of Helsinki. The animals were used in accordance with the Home Office Code of Practice for the Housing and Care of Animals used in Scientific Procedures and were killed by an appropriate humane Schedule 1 method (cervical dislocation).
Three strains of male Zucker rat were used; the lean Zucker control (289 ± 6 g, 6.6 ± 0.3 mmol.L-1 glucose, n = 6), Zucker Fatty (obese, 363 ± 7 g, 10.2 ± 0.6 mmol.L-1, n = 8) and Zucker Diabetic Fatty (ZDF, obese diabetic, 325 ± 7 g, 18.3 ± 1.0 mmol.L-1, n = 8). After sacrifice, adipose tissue was immediately dissected from the subcutaneous abdominal (inguinal), visceral (perirenal) and epididymal adipose depots and immediately stored at -80°C. Blood glucose concentration was measured using a glucometer (Optium Xceed, Abbott Laboratories Ltd., UK).
Patients (23 women and 5 men, this split is representative of the fact that more women were undergoing bariatric surgery at the time) were recruited into one of three groups; those diagnosed with T2M (diabetic, n = 10); patients without diabetes, but with at least three markers of metabolic syndrome (metabolic syndrome, n = 12) ; and those without diabetes and with fewer than two markers of metabolic syndrome (‘healthy’, n = 6). Markers of metabolic syndrome included waist circumference ≥94 cm (male) or ≥80 cm (female); serum triglyceride ≥1.7 mmol.L-1; serum HDL-cholesterol <1 mmol.L-1 (male) or <1.3 mmol.L-1 (female); systolic blood pressure ≥130 mm Hg and/or diastolic blood pressure ≥85 mm Hg; and fasting serum glucose ≥5.6 mmol.L-1. Omental (n = 14) and subcutaneous adipose (n = 28) biopsies approximately 2 cm by 3 cm by 0.5 cm in size were taken atraumatically without heat coagulation. The samples were stored in ice-cold physiological salt solution before immediate transfer to the laboratory and stored within one hour at -80°C. Blood for serum glucose, insulin, triglycerides and cholesterol was processed and analysed routinely at the Royal Derby Hospital Pathology Laboratories.
Blood pressure was measured with subjects rested and supine. Anthropometric measurements performed by one trained person while the patient was standing. Waist circumference was measured at the midpoint between the iliac crest and costal margin, and hip circumference was taken at the widest point around the hips. Neck circumference was measured at the level of the cricothyroid cartilage and arm circumference was measured at the midpoint between the shoulder and elbow. Skinfold thickness was measured at 7 anatomical sites using Harpenden calipers. The 7 sites were: tricep (posterior, level with circumference), bicep (anterior, level with circumference), subscapular (parallel with inferior angle of scapular), suprailiac (immediately superior to iliac crest), abdominal (2 cm to the side of umbilicus), chest (as high as possible between anterior axillary line and nipple) and midaxillary (on midaxillary line, level of xiphoid process of sternum) .
Isolation of mature adipocytes
The method used to obtain mature adipocytes was adapted from Rodbell  as we have previously published  for both human and rat adipose samples. Adipose samples were thawed on ice, added to an equal volume of type II collagenase in phosphate buffered saline (PBS, 1 mg.ml-1, Sigma-Aldrich, UK) and digested at 37°C for 45 minutes. The samples were washed twice in PBS using centrifugation (500 x g, 2 minutes) to separate the mature adipocytes which formed a floating layer. The isolated mature adipocytes were stored at -80°C until homogenisation. Isolated mature adipocytes were homogenised in TE buffer (50 mM Tris, 1 mM EDTA, pH 7.4) using a hand-held glass homogeniser on ice. The homogenates were centrifuged (18,000 x g, 10 minutes) and the supernatant removed and spun again (20,000 x g, 30 minutes). The supernatant layer from this step was then stored at -80°C as the cytosolic fraction. The cellular pellet was homogenised in PBS (10 mM phosphate, 2.7 mM potassium chloride, 137 mM sodium chloride, pH 7.4), centrifuged (20,000 x g, 30 minutes), resuspended and stored at -80°C as the total particulate fraction.
Enzyme activity assays
Enzyme assays were carried out with minor modifications of the method of Boldrup et al.. Samples of the total cell particulate or cytosolic fraction (in duplicate) were diluted in TE buffer (fatty acid free albumin 1 mg.ml-1, pH 7.4) and at 37°C for 10 min with the FAAH inhibitor URB597 (1 μM, Sigma Chemical Company, UK) or vehicle. [3H]-AEA (American Radiolabelled Chemicals, USA) was added to a final concentration of 2 μM, and the samples were incubated at 37°C for 30 min. Activated charcoal (400 μl, 10% w/v in 0.5 M HCl) was used to stop the reaction. After brief centrifugation at approximately 13 000 x g, an aliquot of each supernatant layer was taken for scintillation counting. Tubes without homogenate were run in parallel to establish blank values. The total cell particulate or cytosolic fraction was assayed for MGL activity using the same method as above, substituting a MGL inhibitor, methylarachidonylfluorophosphonate (MAFP, 1 μM, Sigma Chemical Company, UK), and 2-oleoyl-[3H]-glycerol (2-OG, American Radiolabelled Chemicals, USA) to a final concentration of 100 μM and incubated at 37°C for 15 min. Concentrations of substrate (3H-AEA and 3H-2OG) were used at sub-saturating levels in order to allow visualisation of any changes in either substrate affinity or maximal hydrolysis rate.
GraphPad Prism software was used to analyse the data. A D’Agostino & Pearson omnibus normality test was carried out on all data and non-parametric analysis applied where appropriate. Where linear regression was used, the Pearson or Spearman correlation coefficient is reported. When three groups were compared, one-way analysis of variance (ANOVA) was used with Bonferoni multiple comparison (or Krustal Wallis for non-parametric data). For comparison of two groups, either paired or unpaired Student’s t test (or Wilcoxon signed rank test) was used as appropriate.
We would like to thank all the patients who participated in this study. The authors have no competing interests.
- Silvestri C, Ligresti A, Di Marzo V: Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord. 2011, 12 (3): 153-62. 10.1007/s11154-011-9167-3View ArticlePubMedGoogle Scholar
- Di Marzo V, Piscitelli F, Mechoulam R: Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol. 2011, 203: 75-104. 10.1007/978-3-642-17214-4_4View ArticlePubMedGoogle Scholar
- Lipina C, Rastedt W, Irving AJ, Hundal HS: New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance. Bioessays. 2012, 34 (8): 681-91. 10.1002/bies.201200031View ArticlePubMedGoogle Scholar
- Engeli S: Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol. 2012, 209: 357-81. 10.1007/978-3-642-24716-3_17View ArticlePubMedGoogle Scholar
- Devane W, Hanus L, Breuer A, Pertwee R, Stevenson L, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992, 258: 1946-1949. 10.1126/science.1470919View ArticlePubMedGoogle Scholar
- Mechoulam R, Ben-Shabat S, Hanus L, Liumsky M, Kaminski N, Schatz A, Gopher A, Almog S, Martin B, Compton D, Pertwee R, Griffin G, Bayewitch M, Barg J, Vogel Z: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995, 50: 83-90.View ArticlePubMedGoogle Scholar
- Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995, 215: 89-97. 10.1006/bbrc.1995.2437View ArticlePubMedGoogle Scholar
- Cravatt B, Giang D, Mayfield S, Boer D, Lerner R, Gilula N: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996, 384: 83-87. 10.1038/384083a0View ArticlePubMedGoogle Scholar
- Dinh T, Freund T, Piomelli D: A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids. 2002, 121: 149-158. 10.1016/S0009-3084(02)00150-0View ArticlePubMedGoogle Scholar
- Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft F, Sharma A, Jordan J: Activation of the Peripheral Endocannabinoid System in Human Obesity. Diabetes. 2005, 54: 2838-2834. 10.2337/diabetes.54.10.2838PubMed CentralView ArticlePubMedGoogle Scholar
- Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon M, Jordan J, Stumvoli M: Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006, 55: 3053-3060. 10.2337/db06-0812PubMed CentralView ArticlePubMedGoogle Scholar
- Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres J-P, Di Marzo V: Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond). 2007, 31: 692-699.Google Scholar
- Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW: Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One. 2012, 7 (11): e48852- 10.1371/journal.pone.0048852PubMed CentralView ArticlePubMedGoogle Scholar
- Cable JC, Tan GD, Alexander SP, O'Sullivan SE: The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans. Lipids Health Dis. 2011, 10: 129- 10.1186/1476-511X-10-129PubMed CentralView ArticlePubMedGoogle Scholar
- Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V: Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006, 91: 3171-80. 10.1210/jc.2005-2679View ArticlePubMedGoogle Scholar
- Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G, Bozzetto L, Riccardi G, Verde R, Petrosino S, Rivellese AA, Di Marzo V: Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis. 2010, 9: 43- 10.1186/1476-511X-9-43PubMed CentralView ArticlePubMedGoogle Scholar
- Murdolo G, Kempf K, Hammarstedt A, Herder C, Smith U, Jansson PA: Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest. 2007, 30: RC17-21.View ArticlePubMedGoogle Scholar
- Wajchenber BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000, 21: 697-738. 10.1210/edrv.21.6.0415View ArticleGoogle Scholar
- Sarzani R, Bordicchia M, Marcucci P, Bedetta S, Santini S, Giovagnoli A, Scappini L, Minardi D, Muzzonigro G, Dessì-Fulgheri P, Rappelli A: Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism. 2009, 58: 361-7. 10.1016/j.metabol.2008.10.009View ArticlePubMedGoogle Scholar
- Bennetzen MF, Nielsen TS, Paulsen SK, Bendix J, Fisker S, Jessen N, Lund S, Richelsen B, Pedersen SB: Reduced cannabinoid receptor 1 protein in subcutaneous adipose tissue of obese. Eur J Clin Invest. 2010, 40: 121-6. 10.1111/j.1365-2362.2009.02231.xView ArticlePubMedGoogle Scholar
- Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, Vettor R: The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab. 2007, 92: 4810-9. 10.1210/jc.2007-0768View ArticlePubMedGoogle Scholar
- Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003, 425 (6953): 90-3. 10.1038/nature01921View ArticlePubMedGoogle Scholar
- Lauffer LM, Iakoubov R, Brubaker PL: GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. 2009, 58 (5): 1058-66. 10.2337/db08-1237PubMed CentralView ArticlePubMedGoogle Scholar
- Godlewski G, Offertáler L, Wagner JA, Kunos G: Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 2009, 89 (3–4): 105-11.PubMed CentralView ArticlePubMedGoogle Scholar
- You T, Disanzo BL, Wang X, Yang R, Gong D: Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise. Lipids Health Dis. 2011, 10: 194- 10.1186/1476-511X-10-194PubMed CentralView ArticlePubMedGoogle Scholar
- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-5. 10.1161/CIRCULATIONAHA.109.192644View ArticlePubMedGoogle Scholar
- Norton K, Olds T: Measurement Techniques in Anthropometry. Anthropometrica. Edited by: Norton K, Olds T. 1996, Sydney: Anthropometrica. UNSW PressGoogle Scholar
- Rodbell M: Metabolism of isolated fat cells. J Biol Chem. 1964, 239: 375-380.PubMedGoogle Scholar
- Boldrup L, Wilson SJ, Barbier AJ, Fowler CJ: A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Meth. 2004, 60: 171-177. 10.1016/j.jbbm.2004.04.020View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.